Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. has reported significant growth in its Q3 FY25 financials, with revenues reaching $6.8 million, a remarkable 76% increase year-over-year, indicating robust demand for its non-invasive treatment solutions for sleep-disordered breathing. The integration of the SCN has proven beneficial, contributing to a more than doubling of service revenue to $4.6 million, primarily driven by enhancements in sleep testing and treatment-center activities. Furthermore, the company is well-positioned for future growth as it plans to deploy additional service operation teams, with expectations of sustained quarterly revenue increases amid an expanding market, particularly in North America and the rapidly growing Asia Pacific region.

Vivos Therapeutics Inc has experienced a year-over-year revenue decline of 9% in the first half of 2025, attributed largely to its transition to a new sleep center operational model, which has also led to fluctuating quarterly revenues that began declining in the third quarter of 2024. The company's gross margins have decreased to 55% in the second quarter of 2025, driven by discounting practices and unfavorable shifts in product and service mix, indicating pressure on profitability. Furthermore, Vivos faces several risks, including challenges related to sales growth, capital acquisition, customer outreach, sustainable profitability, and potential dilution, combined with a history of operating losses and negative cash flow contributing to ongoing uncertainties about its financial stability.